Spanish dental care provider Dentix is to receive €200m of long-term credit financing from private equity firm KKR to fund its international expansion plans. We speak to CFO Daniel Anton.
Bupa is the second global player to buy in the UK healthcare market this week – its deal for dental group Oasis follows Life Healthcare’s acquisition of Alliance Medical. There are two things that stand out about the deals: the Brexit factor and the premium paid for top-rated management teams.
Bridgepoint-owned UK dentistry chain Oasis Dental Care has sold to Bupa for £835m – an estimated forward EV/EBITDA multiple of over 15x. We speak to a consultant close to the deal about Oasis’s valuation.
As predicted by Healthcare Europa last month, Bupa has bought Oasis Healthcare, the UK’s second largest independent dentistry chain, from Bridgepoint, the European private equity group. The transaction values the business at £835 million. Further consolidation looks likely.
Jiamei Dental Group, which Healthcare Nova understands is the third largest private dental chain in China, says it wants to expand to underserved tier three and four cities. It also aims to grow its online medical services operations and serve more corporate clients.
Spain's special high court, the Audiencia Nacional, has accepted an €18.5m offer from private equity house JB Capital Markets to buy Vitaldent - Spain's largest dentist and Europe's third largest with 341 centres in Spain and another 109 in Italy. Vitaldent has been under judicial review since a tax scandal broke the news in February this year.
There are numerous reports that UK-based insurer and international healthcare provider Bupa is bidding to buy UK dental chain Oasis Healthcare for £500m. One analyst says the deal would make sense.
As reported by Healthcare Europa in June 2016, IK Investment Partners is selling Scandinavian dentist Colosseum Dental, the second largest in the region. There are at least eight bidders involved in the process, mainly private equity houses. But the deal could also attract operator interest.
Medicover, the Pan-East European corporate healthcare provider and lab group, plans to IPO to expand internationally, raising SEK2bn for expansion of its core business into Emerging Markets.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
